India, July 17 -- justify;">Cadila Pharmaceuticals has reiterated that there is no order prohibiting the manufacture, sale, or distribution of its Aciloc 150+ and Aciloc 300+ products. The company continues to comply with all applicable national regulatory requirements and supplies to pharmacies continue uninterrupted. The company said that the active pharmaceutical ingredient has always been clearly and prominently declared on the packaging and labels of all Aciloc products in accordance with applicable labelling requirements. The pharmaceutical company clarified that Aciloc 150+ and Aciloc 300+ contain Famotidine, an H2 receptor antagonist with a favourable pharmacokinetic profile, an established safety record and a rapid onset of actio...